Company News: Study Demonstrates Micromet’s Blinatumomab Produces High Single-Agent Activity in Patients with Relapsed Acute Lymphoblastic Leukemia
– 75% of patients achieved a complete remission, with no evidence of remaining leukemic cells in blood or bone marrow –
– Data add to a growing body of clinical evidence demonstrating blinatumomab’s potential to be used across the course of the disease –
Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet’s blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy. 1 Blinatumomab is the most advanced of a new class of agents called BiTE® antibodies, designed to harness the body’s T cells to kill cancer cells.
Interim results from this phase 2 single-arm trial showed that 75% of patients (9 of 12) achieved a complete remission (CR) or CR with partial recovery of blood counts (CRh*) following treatment with blinatumomab. All nine responding patients achieved a complete molecular response, or had no evidence of leukemic cells in their bone marrow, a key prognostic factor for patient survival. Notably, four patients with genetic abnormalities typically associated with poorer outcomes all achieved a CR or CRh*.
Current treatment for Philadelphia negative relapsed/refractory ALL consists of combinations of toxic chemotherapy drugs that in the majority of cases fail to drive the disease into remission. In more than 30 years, no new drug has been approved for use in this setting, leaving physicians with few options to improve long-term patient outcomes other than variations in the dose and schedule of old drugs with limited efficacy. With current approaches, complete remission rates range from 17-45%. 2-6 Standard chemotherapy is associated with a mortality rate of up to 23%. 7 The average five-year survival rate for adult ALL patients after first relapse is 7%. 5
Click here to read the abstract
- Topp, M.S. et. al. Haematologica. 2011; abstract no. 844
- Kantarjian H, et al. Cancer. 2010;116:5568–5574.
- Advani AS, et al. Br J Haematol. 2010;151(5):430.
- Oriol A, et al. Haematologica. 2010;98(4):589-596.
- Fielding A, et al. Blood. 2007;109(3):944-950.
- O’Brien S, et al. Cancer. 2008;113:3186–3191.
- Bassan R, et al. J Clin Oncol. 2011;29(5):532-543.